Hologic Inc. announced that a recent study shows Low Dose 3-D Mammography exams with C-View software are comparable to traditional Genius 3-D Mammography exams. The study, conducted by University of Pennsylvania researchers and published online in advance of print by Radiology, showed similar overall and invasive breast cancer detection, as well as recall rates.

Dune Medical Devices has been selected as one of the few recipients of a European Union Horizon 2020 research grant to spur development of its biopsy system. The 80 billion euro, seven-year program is aimed at securing Europe’s global competitiveness.

August 25, 2016 — National insurer Cigna revised its medical coverage policy for breast cancer screening and will now cover three-dimensional (3D) mammography for routine breast cancer screening. Under its previous policy, the company covered 3-D mammography for diagnostic purposes, but not for routine screening.

August 25, 2016 — Fujifilm Medical Systems U.S.A. has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for digital breast tomosynthesis (DBT), as an optional software upgrade for the Aspire  Cristalle digital mammography system.

The optional DBT 3-D mammography upgrade for the Aspire Cristalle system, known as Amulet Innovality outside of the United States, has been available since May 2013 in Europe, Asia and Latin America.

August 24, 2016 — Guided Therapeutics Inc. announced in late July that it has sold the first LuViva Advanced Cervical Scan to its distributor in Russia.

The LuViva will be used for marketing clinical studies and for testing as part of the approval process by the Russian Federal Service for Control over Healthcare and Social Development, more commonly known as "Roszdravnadzor." Approval is expected in 2017.

Important clinical trial results in Alzheimer's disease and dementia were recently reported at the 2016 Alzheimer's Association International Conference in Toronto, Canada, including the first completed Phase 3 trial of an anti-tau drug in Alzheimer's.

Molecular Dynamics has successfully completed the first phase of a clinical trial to evaluate the Valiance X12 whole-body cadmium zinc telluride (CZT)-based digital SPECT/CT prototype with promising results.

Purview announced in late July the launch of its new medical image CD burning solution, Purview Publisher.

Subscribe Now